Pfizer $2.3 Billion Settlement (2009)

The government accused Pfizer of orchestrating an illegal scheme to promote a painkiller which was later withdrawn from the market due to safety concerns.

Pfizer allegedly pushed the drug for off-label uses and at dosage levels that the FDA had specifically rejected. The company also faced allegations of providing kickbacks to physicians in exchange for writing prescriptions. These practices caused false claims to be submitted to federal healthcare programs.

The criminal resolution totaled $1.3 billion. This included a criminal fine of $1.195 billion, the largest criminal fine ever imposed in the U.S. for any matter, plus an additional asset forfeiture of $105 million.

The civil settlement was $1 billion to resolve False Claims Act allegations.

John Kopchinski was a former Pfizer sales representative and Gulf War veteran who filed a qui tam lawsuit in 2003.

Appalled by Pfizer’s tactics in selling the painkiller, he sparked a massive government investigation. His lawsuit alleged that Pfizer promoted Bextra for unapproved uses and in unsafe doses, putting patients at risk.

The government joined his case, which became the largest piece of the record $2.3 billion settlement. For his role, Kopchinski received over $51.5 million as a whistleblower reward.

The Pfizer case involved a wide range of drugs. The criminal component centered entirely on Bextra, a painkiller later withdrawn from the market.

Four drugs were central to the civil whistleblower allegations: Bextra, Geodon (an antipsychotic), Zyvox (an antibiotic), and Lyrica (for nerve pain and seizures).

Additional medications, including Aricept, Celebrex, and Lipitor, were also mentioned in connection with the case. Altogether, the settlement involved allegations regarding these and up to nine other Pfizer medicines.

The Pfizer case sent shockwaves through the pharmaceutical industry and permanently changed compliance standards. The record $2.3 billion settlement demonstrated that aggressive off-label marketing would be met with severe financial consequences.

– The five-year Corporate Integrity Agreement required Pfizer to separate sales force compensation from prescription volume, removing a key incentive for improper promotion
– The company was required to implement enhanced compliance training, independent monitoring, and executive accountability measures
– The case set a benchmark for subsequent pharmaceutical settlements, with the government using Pfizer as a template for compliance requirements in later Corporate Integrity Agreements against other manufacturers

John Kopchinski, a former Pfizer sales representative, took the critical step of filing a qui tam lawsuit in 2003 after witnessing the company’s aggressive off-label marketing tactics for Bextra. His firsthand knowledge and willingness to come forward provided the government with the internal evidence needed to build its case.

– Kopchinski documented Pfizer’s illegal promotion of Bextra for unapproved uses and at unsafe dosage levels that the FDA had specifically rejected
– He preserved internal company records and sales materials that detailed the marketing scheme and showed management’s involvement
– His lawsuit became the foundation for the government’s investigation, which ultimately resulted in the record $2.3 billion settlement

The Pfizer settlement is a landmark because it was the largest healthcare fraud settlement in U.S. history at the time. It proved the DOJ would pursue off-label marketing aggressively, even against the biggest pharmaceutical companies.

The case highlighted the power of whistleblowers, as a single former sales representative exposed misconduct leading to billions in recoveries.

The Corporate Integrity Agreement imposed unprecedented compliance obligations that became a blueprint for future settlements. The Pfizer case solidified the False Claims Act as the government’s primary weapon against pharmaceutical fraud and encouraged more whistleblowers to come forward.